These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 38685388)
1. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388 [TBL] [Abstract][Full Text] [Related]
2. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities. Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105 [TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
4. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan. Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073 [TBL] [Abstract][Full Text] [Related]
6. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE; Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978 [TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Flaig TW; Tangen CM; Daneshmand S; Alva AS; Lucia MS; McConkey DJ; Theodorescu D; Goldkorn A; Milowsky MI; Bangs R; MacVicar GR; Bastos BR; Fowles JS; Gustafson DL; Plets M; Thompson IM; Lerner SP Eur Urol; 2023 Sep; 84(3):341-347. PubMed ID: 37414705 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883 [TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen. Liu T; Jiang G Urol Oncol; 2022 May; 40(5):195.e19-195.e25. PubMed ID: 34949512 [TBL] [Abstract][Full Text] [Related]
12. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute. Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111 [TBL] [Abstract][Full Text] [Related]
18. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. Chung DY; Kang DH; Kim JW; Ha JS; Kim DK; Cho KS Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199565 [TBL] [Abstract][Full Text] [Related]
20. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]